Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidance
1. EXEL reported Q1 2025 earnings of 62 cents, surpassing expectations. 2. Quarterly sales reached $555.45 million, beating the consensus of $498.18 million. 3. Cabometyx's demand has surged following FDA approval in neuroendocrine tumors. 4. 2025 revenue guidance raised by $100 million to between $2.25B-$2.35B. 5. EXEL advances into phase 1 study for XB628 in solid tumors.